Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds

Merz Pharmaceuticals

Status and phase: Completed; Phase 4

Conditions: Nasolabial Folds

Treatments: Drug: Hyaluronic acid filler/IMD1 basic

Study type: Interventional

Funder types: Industry

Identifiers

NCT00429520

MRZ 90026-0423/1

Details and patient eligibility

About

Volunteers receive one injection IMD1 basic of correction of nasolabial folds and are followed-up for up to 36 weeks.

Sex: All

Ages: 30 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• main inclusion criteria: severity rating scale grade 3 or 4

Exclusion criteria

• main exclusion criterion: other nasolabial fold corrections within 6 months prior to study entry

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)